Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes

By sjmartinez • March 28, 2023

Epistola R, Sperandio R, Wainberg Z, Iqbal S, Chao J. Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes. Cancer Manag Res. 2023 Mar 18;15:265-275. doi: 10.2147/CMAR.S341468. PMID: 36969544; PMCID: PMC10032141.

Tags: gastric cancer, gastroesophageal junction cancer, Hematology/Oncology, immune checkpoint inhibition, immunotherapy, PD-L1, Publications

A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial)

Kirtane K, Niu J, Blumenschein G, Massarelli E, Hanna GJ, Lee S, Bishop MR, Konecny GE, Mao D, Zheng Y, Rodriguez K, Kim JJ, Williams[...]

A Rare Case of Concurrent Chronic Lymphocytic Leukemia and Therapy-Unrelated Acute Myeloid Leukemia That Evolved From Myelodysplastic Neoplasm

Bansil S, Lai SY, Lo AE, Dietz R Jr, Reed JP. A Rare Case of Concurrent Chronic Lymphocytic Leukemia and Therapy-Unrelated Acute Myeloid Leukemia That[...]

PKA signaling modulates PRMT5/hnRNP A1-mediated IRES translation and dictates responses to mTOR inhibition in glioblastoma

Kumar S, Benavides-Serrato A, Saunders JT, Nishimura RN, Gera JF. PKA signaling modulates PRMT5/hnRNP A1-mediated IRES translation and dictates responses to mTOR inhibition in glioblastoma.[...]